ABSTRACT
[This corrects the article DOI: 10.1155/2018/5706142.].
ABSTRACT
AIM: To evaluate the influence of an intensive course of topical (ophthalmic drops) steroid (dexamethasone disodium phosphate) application on blood glucose levels in diabetic patients. METHODS: Fifty-five diabetic (type 2) patients were randomly assigned to receive either corticosteroid (study group: 30 patients, 1 drop of 0.1% dexamethasone disodium phosphate) or balanced salt solution (BSS; control group: 25 patients) eyedrops, every 2 h for 7 days (8 drops/day). Blood glucose monitoring (venous blood sample) was performed at the same time every day (10:00 a.m.). RESULTS: During the study no side effects (such as hypoglycemic/hyperglycemic crises) were observed in either study or control group. No statistically significant alterations in blood glucose levels were found (p = 0.19, paired t test) in either group. In the corticosteroid group, when we separately examined patients with controlled diabetes mellitus (initial glucose level
Subject(s)
Blood Glucose/metabolism , Dexamethasone/analogs & derivatives , Diabetes Mellitus, Type 2/blood , Diabetes Mellitus, Type 2/drug therapy , Aged , Dexamethasone/administration & dosage , Dexamethasone/adverse effects , Female , Humans , Male , Middle Aged , Ophthalmic SolutionsABSTRACT
PURPOSE: To compare the central corneal thickness (CCT) measurements of patients with neovascular age-related macular degeneration (AMD) and control subjects. METHODS: The CCT value (measured with ultrasound corneal pachymetry) of 130 eyes (130 patients, 1 eye from each patient) with neovascular AMD (AMD group) and 98 eyes (98 patients, 1 eye from each patient) of similar age, sex, and eye's axial length healthy control subjects (normal group) was compared. RESULTS: The mean age (AMD group: 69.1 years vs. control group: 69.5 years, P = 0.81), sex (AMD group: 77 women, 59% vs. control group: 59 women, 60%, P = 0.77), and eye's axial length (AMD group: 25.05-mm vs. control group: 24.61-mm, P = 0.38) of patients with neovascular AMD and healthy control subjects were comparable. There were no statistically significant differences in the mean CCT measurements in the neovascular AMD group in comparison with the control group (549.44 vs. 544.35 microm, P = 0.11). CONCLUSIONS: CCT measurements do not differ in patients with neovascular AMD compared with healthy control subjects.